7/102 sources · 2 publishersUpdated Nov 17, 14:10 UTC
EU approves flexible Libtayo dosing and shorter infusions for Regeneron
The European Commission approved Regeneron’s alternative Libtayo dosing schedule across six cancer indications in the European Union. Patients can receive 700 mg every six weeks after an initial 12 weeks of 350 mg every three weeks, while eligible subsequent infusions can be shortened to 15-30 minutes. A U.S. application for the regimen remains under review, with a decision expected in March 2027.
Why it matters
The EU approval expands dosing flexibility for Libtayo patients and providers, potentially reducing clinic visits and infusion time. The U.S. regimen remains unavailable pending the regulatory review.
Key facts
- 1The European Commission approved the alternative regimen for Libtayo across six EU cancer indications. investing.com
- 2The approved schedule uses 700 mg every six weeks after 12 weeks of treatment with 350 mg every three weeks. investing.com
- 3After a patient tolerates the first 30-minute infusion, subsequent infusion times may be reduced to 15-30 minutes. investing.com
- 4The U.S. supplemental Biologics License Application is under review, with a decision expected in March 2027. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.